Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Rare Disease
Azafaros raises $28 million for lysosomal storage diseases
by Ryan Cross
February 15, 2020
| A version of this story appeared in
Volume 98, Issue 7
The Dutch start-up Azafaros has raised about $28 million in series A financing to develop drugs for lysosomal storage diseases (LSDs), a group of rare metabolic diseases. Some LSDs are treated with enzyme replacement therapies, and many gene therapy firms are developing gene replacement therapies for LSDs. Azafaros is using small molecules discovered by scientists at Leiden University and Amsterdam University Medical Center. Called azasugars, the molecules block the harmful accumulation of glycolipids in LSDs.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter